3.52 USD
↘ 0.16 (4.35%)AT CLOSE (11:59 AM EDT)
Rocket Pharmaceuticals, Inc. Common Stock
RCKTNASDAQ • USD
3.54
↗ 0.02 (0.43%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
3.54
↗ 0.02 (0.43%)
Market: CLOSED
Open?$3.68
High?$3.74
Low?$3.50
Prev. Close?$3.68
Volume?1.9M
Avg. Volume?4.0M
VWAP?$3.57
Rel. Volume?0.47x
Bid / Ask
Bid?$3.52 × 200
Ask?$3.58 × 200
Spread?$0.06
Midpoint?$3.55
Valuation & Ratios
Market Cap?384.1M
Shares Out?109.1M
Float?84.0M
Float %?77.0%
P/E Ratio?N/A
P/B Ratio?1.39
EPS?-$2.04
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.38Strong
Quick Ratio?6.38Strong
Cash Ratio?2.57Strong
Debt/Equity?0.08Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?1.39CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.5CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-80.5%WEAK▾
ROA?-67.5%WEAK▾
Cash Flow & Enterprise
FCF?$-190454000
Enterprise Value?$327.8M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees
202
Market Cap
384.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
NEW YORK, NY 10118
Phone: 646-440-9100